Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

NCT04155541 · clinicaltrials.gov ↗

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR Mutation-positive Inoperable or Reccrent NSCLC

Interventions

DRUG: dacomitinib hydrate

Sponsor

Pfizer